Baidu
map

Oncotarget:膀胱癌侵袭的蛋白质组学分析:靶向EIF3D进行治疗干预。

2017-10-27 fengxiangxin MedSci原创

此研究重点分析了膀胱癌发生侵袭的蛋白质组学变化,旨在更好地了解疾病病理生理学和对药物靶标的鉴定。研究者通过高离析液相色谱联合串联质谱对非肌层浸润性膀胱癌(NMIBC,pTa期)和肌层浸润性膀胱癌(MIBC,阶pT2 +期)患者的组织标本进行了分析。

在目前的医疗策略下,晚期膀胱癌患者的结局不佳。这表明需要更有效的治疗方法进行干预。

这项研究的特点是重点分析了膀胱癌发生侵袭的蛋白质组学变化,旨在更好地了解疾病病理生理学和对药物靶标的鉴定。研究者通过高离析液相色谱联合串联质谱对非肌层浸润性膀胱癌(NMIBC,pTa期)和肌层浸润性膀胱癌(MIBC,阶pT2 +期)患者的组织标本进行了分析。

通过比较分析确定了分析组间的144种差异表达蛋白:除了先前已知的与膀胱癌相关的蛋白质,也有通过进一步免疫组织化学证实的PGRMC1,FUCA1,BROX和PSMD12新型蛋白。通路和相互作用分析预测了在肌层浸润性膀胱癌中与蛋白质合成相关的通路被强烈活化,例如eIF2和mTOR信号通路。

在体外实验中,敲除转移性T24M膀胱癌细胞中的真核翻译起始因子3亚基D(EIF3D)(在肌肉浸润性疾病中过表达)后,细胞增殖、迁移和集落形成均受到抑制,同时减缓了异种移植模型中肿瘤的生长。相比之下,敲除GTP结合蛋白Rheb(EIF3D的上游蛋白)后,体外实验的总体效应与敲除EIF3D相似。

总的来说,这项研究给未来关于NMIBC和MIBC的研究提供了一个资源。研究结果突出了EIF3D可作为一个潜在的治疗靶点。

原始出处:

Latosinska A, Mokou M, Makridakis M.et al.Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-11-11 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2030533, encodeId=a76d2030533b3, content=<a href='/topic/show?id=3d5c663021' target=_blank style='color:#2F92EE;'>#EIF3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6630, encryptionId=3d5c663021, topicName=EIF3D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Fri Dec 15 22:14:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795478, encodeId=2b581e954786f, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Nov 11 16:14:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765678, encodeId=08561e65678ca, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 14:14:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754825, encodeId=5e421e54825e7, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Wed Dec 20 01:14:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297008, encodeId=d1a0129e0085f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336000, encodeId=2322133600069, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sun Oct 29 04:14:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256449, encodeId=52be25644985, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:52:29 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-10-27 131****1460

    学习了受益匪浅

    0

相关资讯

Cell:对肌肉浸润性膀胱癌进行综合的分子特征描述,有助改进疗法

在一项新的研究中,一个来自美国贝勒医学院、布莱根妇女医院、德州大学MD安德森癌症中心、不列颠哥伦比亚癌症研究中心和布罗德研究所等研究机构的研究人员完成了对412种肌肉浸润性膀胱癌样品的综合分子特征描述,从而导致他们鉴定出5种不同的膀胱癌亚型,每种亚型对特定的疗法具有不同的敏感性。这些结果可能导致人们在未来开发出个人化疗法。相关研究结果于2017年10月5日在线发表在Cell期刊上,论文标题为“Co

Sci Rep:血液淋巴细胞染色体异常或可预测膀胱尿路上皮和鳞状细胞癌风险。

血液淋巴细胞中的染色体畸变(CA)已证实与整体癌症风险和老化有关。然而,他们与膀胱癌风险之间的关系尚待阐明。

Eur Urol:预测患者对膀胱内灌注卡介苗免疫治疗的反应

卡介苗(BCG)是目前治疗非侵入性膀胱癌最有效的膀胱内疗法,不仅可以减少复发率,而且可以预防疾病进展和减少死亡。然而,患者对BCG的反应差异很大,并且这取决于诸多因素。

Biomaterials:PLZ4-纳米卟啉可有效用于膀胱癌的治疗

膀胱癌的总体预后在过去30年并没有改善,因此,亟需找到膀胱癌新型诊断和治疗方法。本研究中,研究人员开发了一种多功能纳米卟啉平台,其中涂有膀胱癌特异性配体PLZ4。 单一程序中,PLZ4-纳米卟啉(PNP)可整合光动力学诊断、图像引导光动力学治疗、光热疗法和靶向化疗。PNPs是球形的,相对较小(直径约23nm),近红外光照射时优先发射荧光/热/活性氧。与游离DOX相比,PNPs负载多柔比星(DOX)

J Gene Med:通过靶标基因表达传递的膀胱癌非侵入型检测

由于与检测程序相关的时间耗费和对贫穷病人造成的经济压力,膀胱经检查或者是其他的成像技术在症状表现出来之前不可能用于膀胱癌的检测。作为一种选择,泌尿系肿瘤标记的商业化分析是存在的,但是受限于低灵敏度和高花费。因此,简单的并且是敏感的肿瘤检测方法是需要的,比如通过对尿液的分析。质粒在cmv、cox2或者是opn启动子的控制下可编码分泌性报告因子荧光素酶(G.LUC)。研究人员通过聚乙烯亚胺将这些报告系

Indian J Urol:MicroRNA-21可作为预测非肌肉侵入性膀胱癌复发的分子标记

非肌肉侵入性膀胱癌(NMIBC)的高复发率到目前为止还是一个巨大的挑战。 microRNA-21(miR-21)的超表达在膀胱肿瘤组织和正常粘膜的比较已经有所报道,并且miR-21能以与恶性肿瘤相关的磷酸酶和张力蛋白同源体基因(PTEN)为靶标。最近,有研究人员测试了是否miR-21在膀胱粘膜中的水平可以预测肿瘤复发。在一个前瞻性的群体研究中,研究人员在经尿道膀胱肿瘤切除术中从BC病人中获取了肿瘤

Baidu
map
Baidu
map
Baidu
map